Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck bravecto — Worldwide reported growth YoY (%) (%)
Form 10-Q / 10-K Animal Health MD&A
Latest, FY2025
1.0%
Period ended Dec 31, 2025
Change on a year earlier
-5.0 pts
6.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Bravecto — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.0% | -5.0 pts | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 6.0% | +2.0 pts | Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 4.0% | – | Form 10-K (mrk-20231231.htm, filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). Merck Bravecto — Worldwide reported growth YoY (%) (%), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_bravecto_nom_yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.